

AAMI Consensus Report

**Emergency Use Guidance
for Remote Control of
Medical Devices**

AAMI/CR511:2020

Emergency use guidance for remote control of medical devices

Revisions are expected to be made to this document as the COVID-19 situation evolves. Please go to https://www.aami.org/covid_cr to find the most current version as well as past versions. This document is freely available and may be shared with all interested stakeholders. Contact celliot@ami.org with any comments or questions.

Approved 28 October 2020 by
AAMI

Abstract: The purpose of this document is to provide a general overview of key safety issues to be considered when developing medical equipment under the scope of an FDA emergency use authorization (EUA) such as the FDA Emergency Use Authorization (EUA) on Ventilators, issued March 24, 2020.

Keywords: COVID-19

AAMI Consensus Report

A Consensus Report (CR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) developed to provide concise, prompt and practical guidance on narrowly focused topics of high importance to the health technology community. A Consensus Report is intended provide initial consensus guidance in response to an urgent/immediate need for guidance in the following instances:

- While more robust data/information develops on emergent areas;
- When variation in the development, implementation or use of a product or process exists;
- When existing standards or other documents require additional context/clarification.

A Consensus Report is not subject to the same formal process as a standard and while similar in nature to a technical information report (TIR), a CR is based on the collective knowledge and experience of a selected group of stakeholders and has not undergone the wider reviews of a TIR or standard and offers an even greater response time.

CAUTION NOTICE: This AAMI CR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, technical information reports, consensus reports and other types of technical documents developed by AAMI are *voluntary*, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this document are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Rd, Suite 300, Arlington, VA 22203.

Published by

AAMI
901 N. Glebe Rd., Suite 300
Arlington, VA 22203
www.aami.org

© 2020 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

Publication, reproduction, photocopying, storage, or transmission, electronically or otherwise, of all or any part of this document without the prior written permission of the Association for the Advancement of Medical Instrumentation is strictly prohibited by law. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, visit the [Copyright Clearance Center](#).

Printed in the United States of America

ISBN 978-1-57020-776-1

Contents

Page

Task Group representation iv

Acknowledgements vi

1 Purpose 1

2 References and resources 1

3 Terms and definitions 2

4 Introduction 3

5 Background 4

6 System elements 5

7 Safety requirements and risk control measures 6

Task Group representation

Association for the Advancement of Medical Instrumentation

COVID-19 Response Team Members

This AAMI Consensus Report (CR) was developed by a task group under the auspices of the AAMI COVID-19 Response Team.

The **AAMI COVID-19 Response Team** had the following members:

Cochairs: Jennifer Danieleley
David Feinstein
Julian Goldman
Sandy Weininger

Members: Simona Bancos, FDA/CDRH
Andrew Bath, ResMed Inc.
Brandon Blakely, FDA/CDRH
Brad Bonnette, ECRI Institute
Caitlin Brady, Intertek
David Busch, UT Southwestern Medical Center
Anthony Ciccarello, Philips
Steven Dain, University of Western Ontario
Rakhi Dalal, FDA/CDRH
Jennifer Danieleley, FDA/CDRH
Andy Doering, Medtronic
Simon Dunham, Weill Cornell Medicine
David Feinstein, American Society of Anesthesiologists (ASA)
Bruce Friedman, GE Healthcare
Hamed Ghods, FDA/CDRH
Julian Goldman, Partners HealthCare System
Ralf Heesch, Draeger Medical Systems Inc.
Heidi Horn, Nuvolo Technologies
Fernando Isaza, Philips
Michael Jaffe, Cardiorespiratory Consulting LLC
Gardner Kimm, Medtronic Inc Campus
Robert Kopotic, Edwards Lifesciences
Hubertus Lasthaus, VitalAire Germany
Ed Madsen, Avanos Medical
Phoebe Mainland, Alfred Health
Madeleine Manousaridis, Standards Australia
Benoit Marchal, Air Liquide
Thomas Marmet, GE Healthcare
Debra Milamed, Harvard University
Cyndy Miller, Medtronic Inc Campus
Bryant Moeller, ResMed Inc.
Curtis Morgan, 3M Health Care
Akito Ohmura, Teikyo University-Mizonokuchi Hospital
David Osborn, Philips
John Stark, 3M Health Care
Robert Steurer, Steurer Consulting Group
Dongbo Wang, FDA/CDRH
Sandy Weininger, FDA/CDRH

Ayub Yancheshmeh, CSA Group

NOTE Participation by federal agency representatives in the development of this document does not constitute endorsement by the federal government or any of its agencies.

Acknowledgements

This draft AAMI CR is based on research performed by the Massachusetts General Hospital MD PnP program (and collaborators), which is intended for publication in a scientific journal. The research is being shared as the foundation for this AAMI CR. The research has been funded in part by US gov research contracts (PI - Julian Goldman).

Emergency use guidance for remote control of medical devices

1 Purpose

This document provides design guidance to enable rapid development of remote-control capabilities using an auxiliary Human Machine Interface (HMI) to a medical device for treating patients with COVID-19. This document is intended to guide the regulatory review of these devices.

1.1 Scope

This document provides targeted design guidance to enable rapid development of remote-control capabilities using an auxiliary HMI with a medical device to treat patients with COVID-19. Such devices may include ventilators, infusion pumps, and vital signs monitors.

With respect to this guidance, “remote control” refers to the operation of a medical device from a location not co-located with the patient, device, or its primary HMI. The auxiliary HMI functions as the remote-control and typically includes components inside and outside the patient care environment to allow viewing of data typically displayed on the medical device as well as manipulating device setting. The auxiliary HMI may be connected via wired or wireless communication.

This guidance assumes that remote control and monitoring using an auxiliary HMI will be an additional capability of legally marketed devices that conform to existing safety and performance standards. As such, this document provides guidance only for risks related to implementation of remote control through an auxiliary HMI. It is assumed that the remote control system, whether it is a general-purpose computer or other technology, meets its applicable electrical safety requirements.

This consensus report (CR) includes requirements relevant to the remote control system’s architecture, components, security, usability, and related issues. This CR considers known and foreseeable hazardous situations that could potentially arise from device-control along with appropriate risk control methods.

The requirements outlined in this document presume usage in traditional healthcare facilities (e.g., hospitals, assisted living facilities, nursing homes) as well as spaces converted for the care of COVID-19 patients (e.g., convention centers, university dormitories, motels). This CR presumes that the operators of these devices are trained professional health care workers (HCWs) and not lay persons.

2 References and resources

AAMI TIR57:2016. *Principles for medical device security - Risk management.*

Abad, C, Fearday, A, Safdar, N. *Adverse effects of isolation in hospitalized patients: a systematic review.* J Hosp Infect. 2010;76(2):97-102.

ANSI/AAMI/IEC 60601-1-8:2006 & A1:2012. *Medical electrical equipment – Part 1-8: General requirements for basic safety and essential performance – Collateral Standard: General requirements, tests and guidance for alarm systems in medical electrical equipment and medical electrical systems.*

36 CDC, *Guidelines for Environmental Infection Control in Health-Care Facilities*. (updated July 2019)
37 <https://www.cdc.gov/infectioncontrol/pdf/guidelines/environmental-guidelines-P.pdf>

38 Connor, CW, Palmer, LJ, Pentakota, S. *Remote Control and Monitoring of GE Aisys Anesthesia Machines*
39 *Repurposed as Intensive Care Unit Ventilators*. *Anesthesiology*. 2020;133(2):477-9.

40 Day, HR, Perencevich, EN, Harris, AD, Himelhoch, SS, Brown, CH, Gruber-Baldini, AL, Dotter, E, Morgan,
41 DJ. *Do contact precautions cause depression? A two-year study at a tertiary care medical centre*. *J Hosp*
42 *Infect*. 2011;79(2):103-7.

43 *International Health Facility Guidelines Part B: Version 4 201*
44 http://healthfacilityguidelines.com/ViewPDF/ViewIndexPDF/iHFG_part_c_doors

45 ISO 15817:2012. *Earth-moving machinery - Safety requirements for remote operator control systems*.

46 ISO 14971:2019. *Medical devices -- Application of risk management to medical devices*.

47 IEEE 11703 Part 20601: *Application profile - Optimized Exchange Protocol*.

48 IEEE P11073-10201/D1.1 *Draft Standard for Health informatics - Point-of-care medical device*
49 *communication - Part 10201: Domain information model*.

50 United States (U.S.) Food and Drug Administration (FDA). 2019. *Medical Device Data Systems (MDDS)*.
51 Accessed 29 October 2020. [https://www.fda.gov/medical-devices/general-hospital-devices-and-](https://www.fda.gov/medical-devices/general-hospital-devices-and-supplies/medical-device-data-systems)
52 [supplies/medical-device-data-systems](https://www.fda.gov/medical-devices/general-hospital-devices-and-supplies/medical-device-data-systems)

53 Mehrotra, P, Croft, L, Day, HR, Perencevich, EN, Pineles, L, Harris, AD, Weingart, SN, Morgan, DJ. *Effects*
54 *of contact precautions on patient perception of care and satisfaction: a prospective cohort study*. *Infect*
55 *Control Hosp Epidemiol*. 2013;34(10):1087-93.

56 Morgan, DJ, Pineles, L, Shardell, M, Graham, MM, Mohammadi, S, Forrest, GN, Reisinger, HS, Schweizer,
57 ML, Perencevich, EN. *The effect of contact precautions on healthcare worker activity in acute care*
58 *hospitals*. *Infect Control Hosp Epidemiol*. 2013;34(1):69-73.

59 Stelfox, HT, Bates, DW, Redelmeier, DA. *Safety of patients isolated for infection control*. *JAMA*.
60 2003;290(14):1899-905.

61 UL2800-1, Standard for Safety. *Medical Device Interoperability*, 2019.

62 **3 Terms and definitions**

63 **3.1**

64 **human machine interface**

65 **HMI**

66 an interface for HCW to interact with a medical device

67 **3.2**

68 **auxiliary human machine interface**

69 an interface for HCW to interact with a medical device that is additional to the primary HMI of the medical
70 device

71 **3.3**
72 **primary device (primary medical device)**
73 primary device, or primary medical device, is the device that is located with the patient; primary device
74 includes a primary HMI

75 **3.4**
76 **primary human machine interface**
77 an interface for HCW to interact with a medical device that is co-located with the medical device and the
78 patient

79 **3.5**
80 **remote control**
81 the action to control a medical device by the operators from a location not co-located with the patient,
82 medical device, or its primary HMI

83 **3.6**
84 **remote control system**
85 remote control system typically consists of the auxiliary HMI, the communication link, the receiving unit, the
86 associated software and any accessories required to configure the remote control system such as mounting
87 hardware

88 **4 Introduction**

89 The care of COVID-19 patients requires the use of infection control measures to reduce the transmission
90 of the virus to healthcare workers (HCW) and other patients. These measures include specialized patient
91 isolation rooms and the donning of personal protective equipment (PPE) by a HCW prior to entering the
92 patient's room. The ability to remotely control therapeutic and monitoring devices from outside of the
93 isolation room can:

- 94 a) Reduce the need for entering the patient's room to adjust device settings;
- 95 b) Allow for a response to clinical changes more rapidly;
- 96 c) Enable a more comprehensive real-time patient assessment and management; and
- 97 d) Reduce the donning and doffing frequency of PPE.

98 The benefits of reducing the need for room entries to deliver care include:

- 99 a) Reducing HCW exposure to infectious material;
- 100 b) Improving the quality of patient care;
- 101 c) Reducing consumption of PPE; and
- 102 d) Improving HCW patient-care workflow efficiency thereby increasing HCW availability to provide
103 care for other patients.

104 **5 Background**

105 **5.1 Case for remote control**

106 During pandemics of highly contagious diseases such as COVID-19, the HCW is at a greater risk of infection
107 than the overall population due to their frequency and duration of contact with infected patients. The HCW
108 will enter the patient room to administer care and manage therapeutic equipment. This management may
109 require frequent device adjustments, which may be delayed due to the need for the HCW to protect
110 themselves by donning PPE prior to entering the patient room. PPE may include the use of gowns, gloves,
111 face shields, and boots. PPE is doffed upon leaving the patient room. A recent study (Suen, 2018) reported
112 times of 7 minutes for donning and 10 minutes for doffing, although donning and doffing processes can
113 exceed 15 minutes depending on PPE used.

114 Infectious diseases confer a synergistic burden on and risk to the patient due to the requirements for
115 isolating the patient (Abad et al., 2010), including poorer care and impaired coordination of care (Mehrotra
116 et al., 2013), significantly fewer HCW and family visits (including patients not on precautions) (Morgan et
117 al., 2013), increased rate of adverse events (Stelfox et al., 2003), and increased patient depression
118 (compared to other inpatients, Day et al., 2011). The use of remote control and monitoring can eliminate
119 treatment delays, reduce infection risk to the HCW, help preserve limited supplies of PPE, and improve
120 patient care. In recognition of improved patient care as the result of remote control, the FDA issued an
121 Immediate in Effect Guidance for Ventilators, which notes:

122 *“Hardware and/or software modifications implementing the capability for remote monitoring and remote*
123 *adjustment of ventilator parameters (i.e., adjustment of parameters by trained health care providers from*
124 *outside an isolation unit to avoid unnecessary exposures)” are “examples of circumstances where FDA*
125 *currently believes a modification would not create such undue risk.”* (Enforcement Policy for Ventilators and
126 Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public
127 Health Emergency. Guidance for Industry and Food and Drug Administration Staff, March 2020; IV.B.6.)
128 <https://www.fda.gov/media/136318/download>

129 Other applicable FDA Immediate in Effect Guidance and Emergency Use Authorization documents include:

130 EUA Letter of Authorization - Ventilators, anesthesia gas machines modified for use as ventilators, and
131 positive pressure breathing devices modified for use as ventilators (collectively referred to as "ventilators"),
132 ventilator tubing connectors, and ventilator accessories (March 24, 2020)
133 <https://www.fda.gov/media/136423/download>

134 Ventilator, Ventilator Tubing Connectors, and Ventilator Accessories. Pre-Emergency Use Authorization
135 (EUA)/EUA Interactive Review Template (updated April 21, 2020)
136 <https://www.fda.gov/media/137172/download>

137 Facts Sheets for Healthcare Providers, Emergency Use of Ventilators During the COVID-19 Pandemic
138 (March 24, 2020) <https://www.fda.gov/media/136424/download>

139 Appendix A: Criteria for Safety, Performance and Labeling <https://www.fda.gov/media/136437/download>

140 Enforcement Policy for Infusion Pumps and Accessories During the Coronavirus Disease 2019 (COVID-
141 19) Public Health Emergency, April 2020 <https://www.fda.gov/media/136701/download>

142 Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring
143 During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency (revised June 2020)
144 <https://www.fda.gov/media/136290/download>

145 **5.2 Current practice**

146 Critically ill patients with an infectious disease will often require monitoring and therapeutic support with
147 ventilators and infusion pumps. Although the remote management and the limited control of smart infusion
148 pump settings (with manual confirmation) is available, the remote control capabilities of most commercially
149 available medical devices are quite limited.


150 Examples of remotely controlled ventilator implementations used during the COVID-19 pandemic:

- 151 a) permitted the primary display to be detached and positioned a distance away from the ventilation
152 component using a cable (e.g., Hamilton G5). Off-label modifications to other ventilators have been
153 published, including anesthesia workstations (e.g., GE Aisys and Aisys CS2), which enable the
154 display to be detached for remote control and monitoring (Connor, 2020).
- 155 b) provided a ventilator-specific auxiliary graphic user interface (GUI) via direct cable connection (e.g.,
156 Nihon Kohden NKV550 with Protective Control®, 510(k) cleared by FDA, permits full ventilator
157 operation except silencing the power-off alarm).
- 158 c) provided a custom control software application (e.g., Medtronic Omnitool software for control of
159 compatible PB 980 ventilators) that permits complete remote control over a directly connected or
160 networked Windows OS computer.

161 **6 System elements**

162 **6.1 Construction**

163 The remote control system transmits signals to actuate all needed operating functions for control of the
164 medical device. The remote control unit may display applicable data. Typical components of a remote
165 control system consist of the auxiliary HMI, the communication link, the receiving unit, the associated
166 software and any accessories required to configure the remote control system such as mounting hardware.
167 There can be different interface types for communicating between components and externally to the
168 auxiliary HMI as shown in Figure 1. The controlled device and auxiliary HMI may be directly connected via
169 cables or wirelessly to transmit data, video or control signals.



170 **Figure 1—Different interface types are depicted with a clinician in PPE inside the patient room and**
171 **another clinician without PPE outside the patient room**
172

173 NOTE Clipart from: https://www.123rf.com/clipart-vector/medical_ventilator.html?sti=lvridru068vdkxy2t2j

174 **7 Safety requirements and risk control measures**

175 Risk management shall be performed to consider unsafe states that can arise from introduction of the
176 remote control system and mitigate them to reduce the risks as far as possible to acceptable levels.

177 **7.1 Disclosure of communication architecture**

178 The architecture of communication shall be disclosed with sufficient detail in the Instructions for Use to
179 allow the healthcare delivery organization to verify implementation and acceptably manage risk.

180 Disclosed information shall include whether the remote control system annunciates audible alarm signals.

181 Note 1 Implementation details may be dependent on both the device manufacturer and the health delivery organization's
182 infrastructure. Sufficient detail in this context includes the aspects of the safety requirements in this section.

183 Note 2 Remote control systems may be constructed from constituents from different manufacturers – those manufacturers may
184 address use hazards somewhat differently, e.g., they may provide (1) different ways of informing the operator about the current state
185 and (2) different controls for operating their respective devices.

186 Note 3 The signal pathways in the remote-control system that are relevant to this guidance document are the four paths listed
187 below. The details of the IT network other than those relating to cybersecurity will not be addressed.

188 a) Direct Wire (point to point) — A direct wired connection is a point to point connection with a single cable or multiple cables
189 that transmits bi-directionally the signals required for monitoring and control of the equipment. This type of connection may
190 use pass-through connectors inside and outside the patient room to maintain a negative room pressure.

191 b) Network Connected-Private/Isolated — A network connected (Private/Wired) connection is a connection where the medical
192 electrical equipment inside the room and/or the auxiliary HMI is connected with a cable to a local area network.

193 c) Wireless-Private/Isolated — A wireless local connection is a wireless connection of the equipment inside the room and/or
194 the auxiliary HMI to each other through a network that is isolated from other networks. This connection is typically a Wi-Fi
195 (See IEEE 802.11x) connection.

196 d) Wireless/Wired-Shared network connection

197 Note 4 Example of factors affecting risks for different signal pathways listed above include: EMC, QoS, Cybersecurity, Co-
198 existence, Connector and cabling reliability, Primary/Auxiliary identification.

199 Note 5 Protocols that allow components to transmit information between them can be used to support levels of interoperability (e.g.,
200 syntactic, semantic, conceptual). (See ISO/IEEE 11703-10201)

201 **7.1.1 Degradation or loss of information**

202 Means shall be provided to prevent unacceptable risk arising from degraded or loss of information that is
203 exchanged between the remote control system and the primary medical device.

204 Connection/disconnection of the remote control system shall not interfere with operation of the primary
205 medical device.

206 Note 1 Causes of degradation can include physical interference with the signal (e.g., electromagnetic in origin (EMC), physical
207 integrity (cable issues))

208 Note 2 Causes of QoS degradation can include bandwidth, latency, jitter, packet drop.

209 Note 3 The loss of function of the remote control system whether through loss of mains power or failure of the power supply, or
210 other cause, will disable the auxiliary HMI and potentially lose the display of information, device control, and alarm display and
211 annunciation. Similarly, loss of auditory or visual alarms may reduce the ability of the clinicians to respond in a timely manner.

212 **7.1.2 Conflicting commands**

213 There shall be a means for ME EQUIPMENT to prevent or resolve conflicting control arising from user action
214 on the remote control system.

215 **7.1.3 Wireless coexistence**

216 If the remote control system employs a wireless connection, the manufacturer shall provide evidence of
217 wireless coexistence in the intended environment of use.

218 NOTE See for example:

219 — *Radio Frequency Wireless Technology in Medical Devices Guidance for Industry and Food and Drug Administration Staff*
220 *Document* issued August 14, 2013

221 — [C63.27 Standard for the Evaluation of Wireless Coexistence](#)

222 — [AAMI TIR69: Risk Management of Radio-frequency Wireless Coexistence for Medical Devices and Systems](#)

223 **7.1.4 Authorization of the remote control system communications**

224 When the remote control system communicates with the primary medical device for the first time, there
225 shall be a means to confirm that the auxiliary HMI has the authority to remotely control the primary medical
226 device.

227 **7.2 Component issues and physical hazards**

228 **7.2.1 Basic safety**

229 Means shall be provided to assure basic safety of the remote control system.

230 Medical Electrical (ME) Equipment shall comply with relevant standards.

231 NOTE Remote control system is considered part of the ME system. The basic safety and essential performance aspects of 60601-
232 1 apply. The protection against direct physical hazards under normal and single fault conditions is implied and includes tripping on the
233 components of the system such as the cables and a cart if used.

234 Manufacturer shall disclose the residual risk.

235 **7.2.2 Power**

236 Disclosed information shall include whether the remote control system will operate while the medical device
237 is not connected to mains power.

238 Means may be provided for backup power to the auxiliary HMI.

239 In the event of loss of mains power, the behavior of the auxiliary HMI shall be disclosed. However, loss of
240 power to the remote control system shall not inadvertently affect the operation of the medical device with
241 its primary HMI.

242 NOTE Without backup power, a loss of power will shut down the remote control system and may create a hazardous situation.

243 **7.2.3 EMC**

244 Clause 202 of IEC 60601-1 is recommended but not required.

245 Rationale: The tests of IEC 60601-1-2 are time consuming and expensive and need very specialized
246 equipment. Requiring these tests would delay availability such that new designs might not be available
247 when needed. Disclosure that these tests have not been performed and that other equipment must be kept
248 at a distance should be considered sufficient.

249 Note 1 The hardware used for the remote control system may be vulnerable to radio frequency and electro-magnetic pulses, static
250 discharge, brownouts and voltage spikes. The impact can range from temporary disruption of command and control to permanent
251 damage to circuit boards. Proper shielding, grounding, power conditioning, and/or surge suppression is recommended.

252 **7.3 Locus of control, information focus**

253 **7.3.1 Locus of control**

254 Means shall be provided to manage contention for control from multiple sources.

255 Note 1 Functions which require the direct observation of the patient or physical proximity may not be suitable for control from the
256 auxiliary HMI.

257 Note 2 ME Equipment that was previously designed with one input pathway for data/control (e.g., a medical device front panel by
258 the patient's bedside) will now have at least two input pathways (e.g., the bedside and remote front panel). (adapted from UL-2800-1
259 Annex L)

260 Note 3 ME Equipment that were previously designed with one output pathway for data/control (e.g., a medical device front panel
261 by the patient's bedside) will now likely have at least two pathways (e.g., the bedside and remote device front panel). (adapted from
262 UL-2800-1 Annex L)

263 To allow authorized operators to take over control when necessary, the ability to control critical device settings and modes of operation
264 should be available on both of the operator interfaces of the ME equipment and operator interfaces of the remote control system.

265 The conditions under which locus of control transfer occurs shall be addressed by the risk management process and disclosed.

266 Note 4 Such transfers may be necessary to allow an operator to easily stop, modify, and restart the automated processes
267 controlled by system application logic in case of problems or abnormal situations. disclosure may occur in instructions for use, on
268 operator interface of the ME equipment or on the operator interface of the relevant remote control system as justified by risk
269 management.

270 Note 5 In the event of a remote control system display malfunction, the operator needs to transfer control of the ME Equipment to
271 the bedside.

272 Note 6 The auxiliary HMI may display to an operator who is external to the patient room, all or some of the setting and physiologic
273 information that is available inside the room. Considerations include:

274 a) Do changes to the local control unit (bedside) have priority over the auxiliary HMI or vice versa? Under what conditions
275 should alternate control at the auxiliary HMI be "locked" out?

276 b) Are there any functions that can be performed at the bedside using the local control unit that should be disabled remotely?

277 c) Can all of the controls on the primary control unit be mirrored on the auxiliary HMI? Are there any mechanical settings on
278 one control that are electronic on the other?

279 d) Are there current/active controls that must be easily perceivable to avoid treatment delays and minimize errors?

280 Means shall be provided to indicate that an auxiliary HMI is operational.

281 **7.3.2 Correlation of the remote control system with the primary device**

282 Manufacturers shall take necessary measures to mitigate the risks relating to mistakenly using a remote
283 control system to control a wrong target primary device.

284 Note 1 The risk may be mitigated through a direct cable connection where 1:1 relationship between the remote control system and
285 the target primary device is clear.

286 Note 2 If the remote control is achieved through a wireless connection or network connection, means shall be provided by the
287 manufacturer to allow HCW to clearly identify which primary device is controlled by the remote control system.

288 **7.4 Cybersecurity, access, and privacy**

289 **7.4.1 Cybersecurity risk management**

290 Manufacturer shall perform cybersecurity risk management. Specific cybersecurity risks in relation to the
291 network connection (wired or wireless) between the remote control system and the primary device shall be
292 carefully mitigated.

293 NOTE 1 See for example AAMI TIR57 Principles for medical device security - Risk management. Manufacturer should address
294 confidentiality, integrity, availability, and authentication and consider a defense-in-depth strategy where appropriate.

295 NOTE 2 TCP/IP connections over a general network are not secure. The use of SSL/TLS/HTTPS protocols and SSL certificates
296 should be considered.

297 NOTE 3 TCP ports, not required for the operation of the remote control system, should be locked down. This may include common
298 ports including TCP ports associated with HTTP, POP3, FTP, SMTP and other protocols.

299 NOTE 4 The use of unsecured communication ports on the HMI could allow the connection of malicious devices.

300 NOTE 5 With transmission of patient data to and from an HMI over a network, there is risk for a breach in confidentiality, integrity and
301 availability of the information if the information is not properly secured, the connection not properly authenticated and sufficiently
302 reliable.

303 NOTE 6 The Health Insurance Portability and Accountability Act (HIPAA) requires that all Protected Health Information (PHI) be
304 encrypted when transmitted, and an HCW who fails to properly safeguard PHI can face significant penalties.

305 **7.4.2 User access control**

306 Means shall be provided to control access to the remote control system when it is located in an unsecure
307 location.

308 Note 1 Access and use of the auxiliary HMI remote control system can be limited via physical area control or electronic control
309 mechanisms.

310 Note 2 Remote access risk can also be mitigated with cabling from the therapeutic device directly to an auxiliary HMI outside the
311 room, not connected to any network.

312 Note 3 Unauthorized access to the auxiliary HMI may provide the opportunity to make changes to the patient's therapy leading to
313 serious consequences. Improper access to the auxiliary HMI can lead to any of the following:

314 — Physical theft of data and hardware;

315 — Physical damage or destruction of data and hardware;

316 — Unauthorized changes to the functional environment (e.g., data connections, unauthorized use of removable media,
317 adding/removing resources);

318 — Disconnection of physical data connections;

319 — Undetectable interception or changes of data (command spoofing, keystroke and other input logging, rephrased-from
320 National Institute of Standards and Technology (NIST));

321 — Accidental change (e.g., bumped or tipped).

322 **7.4.3 Patient Visualization**

323 If indicated by risk management, the manufacturer shall provide a means to observe the patient or shall
324 disclose that when the auxiliary HMI is used, the operator must have a means to observe the patient in
325 order to confirm the status of patient and equipment.

326 NOTE Observation may be accomplished by a line-of-sight view of the patient or a video connection, as determined by clinical
327 needs and risk management. In case of a video monitor, HIPAA compliance shall be considered.

328 **7.5 Privacy**

329 Manufacturer shall determine if the auxiliary HMI user access controls have safety requirements, clinical
330 access requirements, and a remotely-controllable feature set.

331 NOTE 1 Patient identifying and care information (such as PHI) may be visible on the HMI display.

332 NOTE 2 For example, the possibility of viewing of PHI on HMI displays by those not associated with the care of the patient.

333 **7.6 Use-related**

334 Foreseeable use errors within the remote control system should be mitigated to reduce the risks as far as
335 possible to an acceptable level. Changes to clinical workflow that result from the use of remote control and
336 data access shall be considered in risk management.

337 **7.6.1 Usability design principles**

338 Operator interfaces provided by the remote control system should be assessed for usability risks and
339 controls provided consistent with recommended or best clinical practices.

340 NOTE Application of IEC 62366-1 and applicable FDA human factors guidance is recommended but not required due to time and
341 resource constraints inherent in delivering EUA products for COVID-19 pandemic patient care.

342 **7.6.2 User interface and controls**

343 An indication of the locus of control should be displayed on the local operator interfaces of both the (local)
344 ME equipment and the remote control system.

345 NOTE Modification of the primary HMI to indicate locus of control may require more time or resources than is feasible during the
346 Pandemic.

347 Information critical to safe remote operation of ME equipment, as determined by a risk management
348 process, shall be accessible through the auxiliary HMI.

349 Data timeliness and consistency shall be considered in risk management.

350 The Instructions for Use shall clearly indicate if displayed data are real-time or historical. In case the
351 displayed data are not real-time, the delay time shall be disclosed in the Instructions for Use.

352 A common clock reference shall be used and displayed on all HMIs.

353 Information critical to safe remote operation shall include operational modes and settings of the ME
354 equipment, and system response to remote user actions, shall be disclosed in the Instructions for Use.

355 NOTE 1 Information critical to safe remote operation includes user instructions for remote operation and variability in network latency.

356 The same operator actions on operator interface controls with similar purposes should produce equivalent
357 effects in conceptually similar situations on both constituent components and ME equipment operator
358 interfaces.

359 The manner in which the following risks are addressed shall be described in the Instructions for Use:

360 a) risks associated with potential confusion from competing loci of control and information, including
361 alarm signals, introduced by the use of the remote control system.

362 NOTE 2 For example, risks should be considered when an alarm signal at the bedside is audio paused when a remote alarm signal
363 is available.

364 NOTE 3 Physical access to the auxiliary HMI may need to be restricted to approved personnel, e.g., through location of physical
365 deployment or through software access controls, considering safety and clinical access requirements.

366 **7.7 Data logging**

367 Realizations of remote control should provide a mechanism to log operator actions and other events with
368 sufficient details as to enable post-hoc reconstruction of user actions in forensic analysis of incidents or
369 system failures. There should be means to log whether commands are local or remote.

370 **7.8 Informational resources**

371 Informational resources necessary to understand feedback or to operate ME equipment when the ME
372 equipment is under remote control should be readily available to the operator.

373 NOTE Informational resources may be provided through labeling, operator manuals, or within the operator interface.